Overall, SR717@RGE-HFn NPs elicited a strong anti-glioma immune response by recruiting immune cells, including cytotoxic T lymphocytes (CTLs), DCs, and NK cells, to enhance antitumor efficacy through a mechanism that was probably dominated by the STING pathway. The gene discussed is STING1; the disease is glioma.